Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
1 hedge funds and large institutions have $918K invested in Jounce Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 83 closing their positions.
99% less capital invested
Capital invested by funds: $64.1M → $918K (-$63.1M)
99% less funds holding
Funds holding: 84 → 1 (-83)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 83
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$9.81M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$7.88M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$5.85M |
| 4 |
BlackRock
New York
|
-$4.71M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.21M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AB
76
Amalgamated Bank
New York
| – | -$7K | -3,951 | Closed |
|
77
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$6.67K | -3,606 | Closed |
|
78
Legal & General Group
London,
United Kingdom
| – | -$6.52K | -3,523 | Closed |
|
79
Simplex Trading
Chicago,
Illinois
| – | -$6K | -3,373 | Closed |
|
|
AIP
80
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$4.78K | -2,585 | Closed |
|
81
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$4K | -2,358 | Closed |
|
82
Osaic Holdings
Scottsdale,
Arizona
| – | -$4.35K | -2,350 | Closed |
|
|
CB
83
Community Bank
Dewitt,
New York
| – | -$1.84K | -1,000 | Closed |
|
84
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$1K | -562 | Closed |
|
JNCE Hedge Fund Activity: Q2 2023 in Review
1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2023, worth a combined $918K — down 99% from $64.1M a quarter earlier.
Sellers outnumbered buyers: 83 funds closed out of JNCE and 0 opened new positions — a net loss of 83 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Tang Capital Management, exiting entirely with an estimated $9.81M sold.
- 1 institutional investor held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2023, down from 84 in Q1 2023.
- Funds reported $918K of Jounce Therapeutics, Inc. Common Stock stock for Q2 2023, down 99% quarter-over-quarter.
- 0 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2023 and 83 closed out, a net change of -83 holders.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2023 was Tang Capital Management, an estimated $9.81M sold.
Based on aggregated 13F filings for Q2 2023.